IP Library Granted Patent US 7,622,464
Granted Patent B2
US 7,622,464 · App. 10/509,162 · Granted Nov 24, 2009

Morpholinyl-urea derivatives for use in the treatment of inflammatory diseases

Assignee: Glaxo Group Limited
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,622,464
App. No.
10/509,162
Granted
Nov 24, 2009
Kind
B2
Abstract

Compounds of formula (I): wherein: R 1 represents substituted or unsubstituted heteroaryl; Y represents —(CR na R nb ) n —; R na and R nb are each independently hydrogen or C 1-6 alkyl; n is an integer from 0 to 5; R 2 represents unsubstituted or substituted aryl or unsubstituted or substituted heteroaryl; R 3 and R 4 each independently represent hydrogen or C 1-6 -alkyl; R 7 represents hydrogen or C 1-6 alkyl; R 8 represents hydrogen or C 1-6 alkyl; and salts and solvates thereof; are CCR3 antagonists and are thus indicated to be useful in therapy.

Claims (18)

1. A compound of formula (If)

wherein;

R 1f is unsubstituted furanyl or furanyl substituted with oxadiazolyl, methyl-substituted oxadiazolyl, or methyl-substituted triazolyl, carboxy, C 1-6 alkoxycarbonyl, or (mono- or di-C 1-6 alkyl)aminocarbonyl; or thiophenyl substituted with (mono- or di-C 1-6 alkyl)aminocarbonyl, C 1-6 alkoxycarbonyl, or carboxy;

R 2f is 3,4-dichlorophenyl or 3,4-difluorophenyl, and;

R 7f is hydrogen or methyl;

or a salt thereof,

with the proviso that the compound is not N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}-N′-(2-furylmethyl)urea.

2. A compound of Formula (If) according to claim 1 wherein R 1f is 3-(1,3,4-oxadiazol-2-yl)furan-5-yl, furan-2-ylmethylene, 4-(3-methyl-1,2,4-oxadiazol-5-yl)furan-2-yl, 4-(3-methyl-1,2,4-triazol-5-yl)furan-2-yl, 4-(2-methyl-1,3,4-oxadiazol-5-yl)furan-2-yl, 2-carboxyfuran-5-yl, 2-ethoxycarbonylfuran-5-yl, 2-methylaminocarbonylfuran-5-yl, 2-ethylaminocarbonylfuran-5-yl, 2-iso-propylaminocarbonylfuran-5-yl, 3-methylaminocarbonylfuran-5-yl, 3-ethylaminocarbonylfuran-5-yl, 3-iso-propylaminocarbonylfuran-5-yl, 2-methylaminocarbonylthiophen-5-yl, 2-ethylaminocarbonylthiophen-5-yl, 2-iso-propylaminocarbonylthiophen-5-yl, 2-methylaminocarbonylthiophen-4-yl, 2-ethylaminocarbonylthiophen-4-yl, 2-iso-propylaminocarbonylthiophen-4-yl, 2-methoxycarbonylthiophen-4-yl, 2-carboxythiophen-4-yl, 2-methoxycarbonylthiophen-5-yl, 2-carboxythiophen-5-yl, 3-ethoxycarbonylfuran-5-yl, 3-carboxyfuran-5-yl, 3-iso-propylaminocarbonylthiophen-5-yl, 3-ethylaminocarbonylthiophen-5-yl, or 3-methylaminocarbonylthiophen-5-yl.

3. A compound of Formula (If) according to claim 1 wherein the stereochemistry at the position marked “*” is RS or S.

4. A compound of Formula (If) according to claim 2 wherein the stereochemistry at the position marked “*” is RS or S.

5. A compound of Formula (If) according to claim 1 wherein the stereochemistry at the position marked “**” is RS, R, or S.

6. A compound of Formula (If) according to claim 2 wherein the stereochemistry at the position marked “**” is RS, R, or S.

7. A compound of Formula (If) according to claim 3 wherein the stereochemistry at the position marked “**” is RS, R, or S.

8. A compound of Formula (If) according to claim 4 wherein the stereochemistry at the position marked “**” is RS, R, or S.

9. A compound which is: 5-[({[({(2S)-4-[(3,4-dichlorophenyl)methyl]-2-morpholinyl}methyl)amino]carbonyl}amino)methyl]-N-methyl-3-furancarboxamide.

10. A compound which is: 5-[({[({(2S)-4-[(3,4-dichlorophenyl)methyl]-2-morpholinyl}methyl)amino]carbonyl}amino)methyl]-N-(1-methylethyl)-3-furancarboxamide.

11. A compound which is: 5-[({[({(2S)-4-[(3,4-difluorophenyl)methyl]-2-morpholinyl}methyl)amino]carbonyl}amino)methyl]-N-ethyl-3-furancarboxamide.

12. A compound which is: 5-{3-[(2S)-4-(3,4-Dicholorobenzyl)-morpholin-2-ylmethyl]-uriedomethyl}-thiophene-3-carboxylic acid methylamide.

Assignments (2)
CHANGE OF ADDRESS Recorded Apr 16, 2025
From: GLAXO GROUP LIMITED
To: GLAXO GROUP LIMITED
Reel/Frame 071044/0904 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 24, 2005
From: ANCLIFF, RACHAEL ANN; COO, CAROLINE MARY; ELDRED, COLIN DAVID; GORE, PAUL MARTIN; HARRISON, LEE ANDREW; HAYES, MARTIN, ALISTAIR; HODGSON, SIMON TEANBY; JUDD, DUNCAN BRUCE; KEELING, SUZANNE ELAINE; LEWELL, ZIAO QING; MILLS, GAIL; ROBERTSON, GRAEME MICHAEL; SWANSON, STEPHEN; WALKER, ANDREW JOHN; WILKINSON, MARK
To: GLAXO GROUP LIMITED
Reel/Frame 015619/0687 →
Priority Claims (2)
GB 0207434.2 · Mar 28, 2002 · national
GB 0301608.6 · Jan 24, 2003 · national
Continuity (1)
Related Publication 20060063765A1 · Mar 23, 2006